Accepted Article

Title: Opto-epigenetic modulation of DNA methylation with a photo-responsive small-molecule approach

Authors: Ha Phuong Nguyen, Sabrina Stewart, Mikiembo N Kukwikila, Sioned Fôn Jones, Daniel Offenbartl-Stiegert, Shiqing Mao, Shankar Balasubramanian, Stephan Beck, and Stefan Howorka

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Angew. Chem. Int. Ed. 10.1002/anie.201901139
Angew. Chem. 10.1002/ange.201901139

Link to VoR: http://dx.doi.org/10.1002/anie.201901139
http://dx.doi.org/10.1002/ange.201901139
Opto-epigenetic modulation of DNA methylation with a photo-responsive small-molecule approach**

Ha Phuong Nguyen\(^1\), Sabrina Stewart\(^2\), Mikiembo N. Kukwikila\(^1,3\), Sioned Fon Jones\(^1\), Daniel Offenbartl-Stiegert\(^1\), Shiqing Mao\(^4,5\), Shankar Balasubramanian\(^4,5\), Stephan Beck\(^2\), Stefan Howorka\(^1*\)

Controlling the functional dynamics of DNA within living cells is essential in biomedical research. Epigenetic modifications such as DNA methylation play a key role in this process. Controlled DNA methylation editing can be attained via genetic means. Yet there are few chemical tools available for the spatial and temporal modulation of this modification. Here we present a small-molecule approach to modulate DNA methylation with light. The strategy uses a photo-tunable version of a clinically used drug (5-aza-2′-deoxycytidine) to alter the catalytic activity of DNA methyltransferases, the enzymes that methylate DNA. After uptake by cells, the photo-regulated molecule can be light-controlled to reduce genome-wide DNA methylation levels in proliferating cells. The chemical tool complements genetic, biochemical and pharmacological approaches to study the role of DNA methylation in biology and medicine.

The methylation of DNA at position 5 of cytosines is chemically a very simple but biologically one of the most important modifications of DNA. It influences many biological processes in humans such as the regulation of cell function, cellular reprogramming, and organismal development\(^{[1-7]}\). Biological effects of higher methylation levels at promoters are mediated by lowering the transcription of genes either via blocking binding of transcription factors, or by recruiting unique methyl-recognizing proteins that lower gene expression. Altered levels of methylation are also associated with several diseases\(^{[8-12]}\) including cancer\(^{[8,12-16]}\).

Driven by the growing importance of DNA methylation in biomedical research, there is a strong interest to experimentally lower or increase methylation levels\(^{[17-23]}\) to study, for example, the role of epigenetic reprogramming in tissue development or regenerative medicine\(^{[24-25]}\). Optical control is of particular relevance given the high spatial and temporal resolution of light. Often, the approach is implemented with photosensitive small molecules of tuneable bioactivity\(^{[26-31]}\). These can be used without the need for genetic engineering of cells leading to powerful applications within cell biology\(^{[32]}\). Yet, despite the importance of DNA methylation in biology, no light-tunable small-molecule tool has been developed to manipulate methylation levels in cells.

Here we present a photo-mediated small-molecule strategy that modulates methylation in light-exposed cells. At the approach’s centre is an inhibitor that interferes with DNA methyltransferases (DNMTs), the enzymes responsible for DNA methylation\(^{[33]}\) including the maintenance DNA methyltransferase 1 (DNMT1)\(^{[34]}\). The inhibitor’s bioactivity becomes tuneable with light by chemical derivatization with a photocage. As schematically illustrated in Figure 1a, the attached photocage renders the inhibitor biologically inactive. However, light exposure cleaves off the photocage to restore the original inhibitory effect (Figure 1a). The photocaged molecule is hence expected to maintain methylation levels in the dark, while light should decrease methylation levels following replication of cells\(^{[35]}\) (Figure 1a).

Controlling DNA methylation is an essential step in many biological processes, ranging from the regulation of gene expression to the development of cancer. Traditional methods, such as genetic engineering, have limitations in terms of spatial and temporal control. However, with the growing importance of DNA methylation in biology and medicine, there is a need for more precise and controllable approaches.

**This article is protected by copyright. All rights reserved.**
Our approach was implemented with DNMT inhibitor 5-aza-2'-deoxyxycytidine (dAC, decitabine)\textsuperscript{[35-36]} (Figure 1b). The cytidine analogue is a clinically used drug for myelodysplastic syndromes\textsuperscript{[37]} and is being tested against leukemia and solid tumors\textsuperscript{[18,38]} and as a sensitizer for immunotherapies\textsuperscript{[39-40]}. dAC is the best choice for the photocaging approach given its high inhibitory effect on DNMT\textsuperscript{[41]} even though it is also known to undergo slow hydrolysis at the 5-aza-base ring\textsuperscript{[42]}. To exert its inhibitory effect after cellular uptake, dAC is phosphorylated by deoxycytidine kinase in a rate-limiting step\textsuperscript{[43]}. Subsequent phosphorylations to triphosphate lead to the polymerase-mediated incorporation into DNA\textsuperscript{[44]} where the 5-aza-base ring forms an covalent adduct with DNMT. This adduct prevents methylation of DNA in replicating cells but also targets DNMT for proteosomal degradation\textsuperscript{[45]}. Given the tight fit inside the active site of deoxycytidine kinase (Figure S1), we surmised that photocaging dAC would block the rate-limiting step of phosphorylation and hence abolish inhibition of DNMT.

To optically control the activity of dAC, we attached a photocage to each of all possible coupling sites within the nucleoside: the exocyclic NH\textsubscript{2} group of the base, and the 3' and 5' OH groups of the deoxyribose (Figure 1b)\textsuperscript{[27,31]}. All three positions were modified as the resulting steric blockade was expected to hinder binding of dAC into the active site of deoxycytidine kinase (Figure S1). For the chemical derivatization, photocage diethylaminocoumarinyl-4-methyl (DEACM) (Figure 1b) was used given its favorable high extinction coefficient (ε = 16,000 M\textsuperscript{-1} cm\textsuperscript{-1}) and long absorption wavelength (λ = 365 nm) that ensure biocompatibility by avoiding mutagenic irradiation at high intensity in the UV spectral region.

Three DEACM derivatives of dAC 1a, 2, and 3 (Figure 1b) were synthesized. In 1a, the photocage is attached via a carbamate bond to NH\textsubscript{2}, while the linkage in 2 and 3 is mediated via a carbonate to 5' and 3' OH, respectively (Figure 1b). The synthetic routes to 1a, 2, and 3 are described in the Supporting Methods.

Additional photocaged compounds were made to demonstrate that the synthetic route is generic. For example, synthesis of 1b and 1c carrying a nitrophenyl group on the amino group (Figure 1b) showed that a chromophore other than DEACM can be attached to dAC. 1b and 1c also served as reference compounds for the spectroscopy analysis (see below). Similarly, preparation of nitrophenyl-modified azacytidine 1d (Figure 1b) proved that the clinically used ribonucleotide version of dAC can be equipped with a photocage (see Supporting Methods for synthetic routes of 1b-d).

DEACM-dAC derivatives 1a, 2, and 3 were examined to probe whether the spectroscopic properties are influenced by the chromophore’s attachment site. As shown in Figure 2a, all compounds exhibited strong absorption at a biocompatible wavelength of λ = 365 nm (Table 1) with ε close to unconjugated DEACM (ε = 7000 M\textsuperscript{-1} cm\textsuperscript{-1}, Figure S2)\textsuperscript{[45]} implying minimal influence by coupling to dAC. The data for compounds 1b-d showed similar findings (Table 1, Figure S2).

Uncaging efficiency, by contrast, was influenced at which site of dAC the chromophore was attached. The analysis (Figure 2b) revealed for compound 1a a fast uncaging rate of k = 1.03 x 10\textsuperscript{3} s\textsuperscript{-1} equivalent to a 50% recovery of dAC within a half-life of t\textsubscript{1/2} = 11 min (Figure 2c) while 2 was slower (Figure 2c, Figure S3), possibly due to a quenching interaction between the photocage and proximal triazine nucleobase. In support, 3 with DEACM at more distant 3' OH to triazine had a fast photolysis with t\textsubscript{1/2} = 8 min (Figure 2b and 2c, Figure S3). The likely mechanism for uncaging is shown in Figure S4.

**Figure 2.** Spectroscopic and photochemical analysis of photocaged dAC versions 1a, 2, and 3. (a) UV-vis absorption spectra of photocaged dAC compounds 1a, 2, and 3 at 50 µM in DMSO/Water (5/95). (b) HPLC traces for the photodeprotection of 1a. The initial peak corresponding to caged 1a disappears upon irradiation at 365 nm to yield uncaged dAC and free DEACM-OH. The rates for photo-induced uncaging were determined by exposing the DEACM-dAC conjugates to light at λ = 365 nm of moderate intensity at 145 µW cm\textsuperscript{-2} and at ambient temperature of 25 °C. (c) Time course for photo-induced uncaging of 1a, 2 and 3 at λ = 365 nm.
Successful uncoupling of the photocage from the nucleobase was also found for control nucleotides 1b–d whose spectroscopic and photolytic properties were in line with literature value for nitrophenyl (Table 1 and Figure S3). Nevertheless, the uncaging rates of 1b–d are too low for subsequent cell work. By comparison, compound 3 has a high absorption wavelength and the fastest photolysis.

Analysis of 3 determined its stability in the absence of light. Unmodified dAC is known to have a slightly reduced stability due to hydrolysis at the 5-aza-base ring leading to a half-life of 2200 min at 25 °C[42]. By comparison, 3 had a half-life of 690 min 25 °C which reflects partial hydrolysis of the ring and the carbonate linkage to the photocage, as determined by MS (Figure S5). This half-life is almost 70-times longer than the half-life for photo-induced uncaging of 3 and 7-times longer than the subsequent incubation duration to cells. This means that after 1 h of light-induced deprotection, only 3% or less of compound 3 are still in the caged form. Dark instability is hence not compromising photouncaging. Reflecting its adequate stability and fast deprotection rate under illumination, compound 3 was used for subsequent biological investigations.

To test whether methylation levels in cells can be controlled with light, 3 was added to hypermethylated human cancer cell lines SaOS2 and T24[46]. Additional exposing cells to light was expected to induce passive demethylation due to photo-uncaging of 3 and the resulting non-methylation during DNA replication in dividing cells (Figure 3b). Lack of illumination was anticipated to maintain methylation (Figure 3a). Consequently, cells were incubated with 0.1 μM 3 and either illuminated for 1 h at 365 nm and 25 °C, or kept in the dark at 25 °C. Treatment of cells with unmodified dAC served as positive control for demethylation (Figure 3c). After incubation with the small molecules, the medium was changed, cells were grown at 37 °C for 24 h, genomic DNA was isolated and enzymatically digested, and the nucleotide content analysed with Liquid Chromatography coupled with tandem Mass Spectrometry (LC-MS).

Figure 3d and 3e summarize the cellular levels of methylated C as percentage of the total cytosine pool for SaOS2 and T24 cells, respectively. Exposure to 3 without illumination maintained a high level of methylated DNA (Figure 3d and 3e, 3), thereby confirming that photocaged dAC was biologically inactive at the tested conditions. However, incubation with 3 and simultaneous exposure to light caused a drastic reduction in methylated DNA (Figure 3d and 3e, 3-light) to a level almost identical to uncaged dAC (Figure 3d and 3e, dAC), while light exposure in the absence of 3 did not affect methylation (Figure 3d and 3e, 0). The data demonstrate that our strategy of light-induced demethylation is successful; by photolysis of 3, dAC’s biological inhibition was reactivated to block DNA methyl transferases within cells. Our approach was also confirmed by demethylation at a concentration of 0.5 μM 3 (Figure S6). At 1.5 μM or higher, the compound leads to demethylation without light exposure, possibly because 3 is hydrolytically inactivated by enzymes. Control experiments where cells were solely exposed to light did not lead to altered methylation levels (Figure S6; 0 μM 3).

Molecular analysis confirmed the proposed mechanism for 3’s attainment of lower methylation levels in light-exposed cells. First, an enzymatic assay established that the photocage in 3 interferes with deoxycytidine kinase activity. The kinase usually phosphorylates 5’ OH of uncaged dAC[43] after the compound is taken up by cells. However, the photocage attached to 3’ OH of 3 prevents the compound’s phosphorylation (Figure S7) most likely due sterically hindering access of 3 to the enzyme’s active site (Figure S1). In addition, Western blot analysis confirmed that uncaged 3 lowers methylation by decreasing levels of the DNA methyltransferase 1 (Figure S8). The amount of DNMT1 was reduced when cells were exposed to 0.1 μM 3 and light to liberate dAC. The inhibitor’s mode of action is thought to involve its incorporation into DNA to form a covalent adduct with DNMT1[43] which prevents methylation of DNA in replicating cells but also targets DNMT for proteosomal degradation[44].

### Table 1. Spectroscopic and photolytic properties of photocaged DNMT inhibitors.

| Compound | λ\text{max} (nm) | ε\text{max} (M⁻¹ cm⁻¹) | ε° (M⁻¹ cm⁻¹) | k / s⁻¹ | t₁/₂ (min) | Φ\text{max} (%) | ε° Φ\text{max} (%) |
|----------|-----------------|--------------------------|---------------|----------|------------|----------------|-------------------|
| 1a       | 391             | 10000                    | 11000         | 7000     | 1.03×10⁻²  | 11             | 6.11×10⁻⁴        | 427                |
| 1b       | 233             | 16400                    | 9000          | 200      | 8.33×10⁻⁰  | 139            | 4.93×10⁻⁴        | 0.99               |
| 1c       | 348             | 5000                     | 10400         | 4000     | 6.67×10⁻⁰  | 173            | 3.94×10⁻⁴        | 16                 |
| 1d       | 260             | 14800                    | 12100         | 460      | 1.00×10⁻⁴  | n/a            | n/a              | n/a                |
| 2        | 395             | 11000                    | 11400         | 7300     | 4.83×10⁻⁴  | 24             | 2.88×10⁻²        | 210                |
| 3        | 392             | 12000                    | 11700         | 8100     | 1.50×10⁻⁵  | 8              | 8.64×10⁻⁴        | 716                |

* Wavelength of maximum absorption (nm). * Molar absorbptivities (M⁻¹ cm⁻¹) at λ\text{max}, 254 nm, or 365 nm. * Deprotection-rate constant for irradiation at 365 nm, or at 254 nm as indicated by *.* Quantum yield of uncaging at λ = 365 nm. * Product of molar absorbance coefficient and quantum yield of uncaging at λ = 365 nm in M⁻¹ cm⁻¹.
to be the best in terms of high wavelength absorption and photolytic efficiency, while carbonate or carbamate-tethered nitrobenzyl 1b-1d were not suitable, similar to previously tested ether-based linkages. In practical terms, this insight could improve the future synthesis of photocaged versions of the clinically tested dAC-related drugs such as SGI-110 [54]. Finally, dAC and related drugs could be modified with photoswitches that regulate bioactivity via photoisomerable conformation changes rather than photolysis [26-29].

The optically addressable DNMT inhibitor may be developed into a potentially valuable research tool for studying epigenetic mechanisms in health and disease. Areas of interest include regenerative medicine [55], developmental biology [56], development and progression of cancer [57], and the development of therapeutic routes [18,31-37,58] to treat surface-accessible tissues [59]. Before realizing the potential, the photocaged nucleoside’s bioavailability has to be successfully tested and its stability may have to be improved, such as replacing the carbonate tether with self-immolating linkages [60-63]. In the case of thicker tissues or organs, high-wavelength photocages active in the optical window need to be devised. In conclusion, our photocaged DNMT inhibitor opens up exciting new avenues in basic and clinical research for epigenetics but also the synthesis of photo-controlled molecules.

Acknowledgments

The authors would like to thank Gurpreet Virdi for the synthesis and characterisation of 3'-DEACMOC-deoxycytidine (3CdC) and Dr. Jonathan R. Burns for generating all images.

Keywords: DNA, cytosine, methylation, photo-caging, epigenetics

[1] P. A. Jones, Nat. Rev. Genet. 2012, 13, 484-492.
[2] A. Meissner, T. S. Mikkelsen, H. C. Gu, M. Wernig, J. Hanna, A. Svachenko, X. L. Zhang, B. E. Bernstein, C. Nusbaum, D. B. Jaffe, A. Gnirke, R. Jaenisch, E. S. Lander, Nature 2008, 454, 766-770.
[3] R. Meltivet, R. Gallais, C. Tiffonco, C. Le Peron, R. Z. Jurkowski, R. P. Carmouche, D. Ibberson, P. Barath, F. Demay, G. Reid, V. Benes, A. Jeltsch, F. Gannon, G. Salbert, Nature 2008, 452, 45-50.
[4] K. K. Geyer, C. M. Rodriguez Lopez, T. Chalimena, S. E. Munshi, M. Jeltsch, J. M. Wilkinson, N. Katifol, A. P. Truscott, J. Heald, M. J. Wilkinson, K. F. Hoffmann, Nat. Commun. 2011, 2, 424.
[5] Z. D. Smith, A. Meissner, Nat. Rev. Genet. 2013, 14, 204-220.
[6] D. D. De Carvalho, J. S. You, P. A. Jones, Trends Cell Biol. 2010, 20, 609-617.
[7] J. S. Hardwick, D. Pichelinek, A. H. El-Sagheer, I. Tear, D. Singleton, S. E. V. Phillips, A. N. Lane, T. Brown, Nat. Struct. Mol. Biol. 2017, 24, 544-552.
[8] A. P. Feinberg, Nature 2007, 447, 433-440.
[9] V. K. Radyan, T. A. Down, D. J. Balding, S. Beck, Nat. Rev. Genet. 2011, 12, 529-541.
[10] K. D. Robertson, Nat. Rev. Genet. 2005, 6, 597-610.
[11] G. Egger, G. Liang, A. Aparicio, P. A. Jones, Nature 2004, 429, 457-463.
[12] C. Plass, S. M. Pfister, A. M. Lindroth, O. Bogatyrova, R. Claus, P. Lichter, Nat. Rev. Genet. 2013, 14, 765-780.
[13] J. G. Herman, S. B. Baylin, New. Engl. J. Med. 2003, 349, 2024-2025.
[14] M. Esteller, New. Engl. J. Med. 2008, 358, 1148-1159.
[15] P. A. Jones, S. B. Baylin, Cell 2007, 128, 683-692.
[16] M. Ehrlich, Epigenomics 2009, 1, 239-259.
[17] M. L. Maeder, J. F. Angstman, M. E. Richardson, S. J. Linder, V. M. Casico, S. Q. Tsai, O. H. Ho, J. D. Sander, D. Reyon, B. E. Bernstein, J. M. L. Macder, F. Costello, M. F. Wilkinson, J. K. Joung, Nat. Biotechnol. 2013, 31, 1137-1142.
Keywords: DNA, methylation, epigenetics, photocage, 5-aza-2'-deoxycytidine, decitabine